Literature DB >> 9789727

Gout in the elderly. Clinical presentation and treatment.

A G Fam1.   

Abstract

Gout in the elderly differs from classical gout found in middle-aged men in several respects: it has a more equal gender distribution, frequent polyarticular presentation with involvement of the joints of the upper extremities, fewer acute gouty episodes, a more indolent chronic clinical course, and an increased incidence of tophi. Long term diuretic use in patients with hypertension or congestive cardiac failure, renal insufficiency, prophylactic low dose aspirin (acetylsalicylic acid), and alcohol (ethanol) abuse (particularly by men) are factors associated with the development of hyperuricaemia and gout in the elderly. Extreme caution is necessary when prescribing nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of acute gouty arthritis in the elderly. NSAIDs with short plasma half-life (such as diclofenac and ketoprofen) are preferred, but these drugs are not recommended in patients with peptic ulcer disease, renal failure, uncontrolled hypertension or cardiac failure. Colchicine is poorly tolerated in the elderly and is best avoided. Intra-articular and systemic corticosteroids are increasingly being used for treating acute gouty flares in aged patients with medical disorders contraindicating NSAID therapy. Urate-lowering drugs are indicated for the treatment of hyperuricaemia and chronic gouty arthritis. Uricosuric drugs are poorly tolerated and the frequent presence of renal impairment in the elderly renders these drugs ineffective. Allopurinol is the urate-lowering drug of choice, but its use in the aged is associated with an increased incidence of both cutaneous and severe hypersensitivity reactions. To minimise this risk, allopurinol dose must be kept low. A starting dose of allopurinal 50 to 100mg on alternate days, to a maximum daily dose of about 100 to 300mg, based upon the patient's creatinine clearance and serum urate level, is recommended. Asymptomatic hyperuricaemia is not an indication for long term urate-lowering therapy; the risks of drug toxicity often outweigh any benefit.

Entities:  

Mesh:

Year:  1998        PMID: 9789727     DOI: 10.2165/00002512-199813030-00006

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   4.271


  66 in total

1.  Urate-mediated inflammation in nodal osteoarthritis: clinical and roentgenographic correlations.

Authors:  E V Lally; B Zimmermann; G Ho; S R Kaplan
Journal:  Arthritis Rheum       Date:  1989-01

2.  Diuretic-induced gout: the beginnings of an epidemic?

Authors:  P N Platt; W C Dick
Journal:  Practitioner       Date:  1985-03

3.  Current therapy of acute microcrystalline arthritis and the role of corticosteroids.

Authors:  A G Fam
Journal:  J Clin Rheumatol       Date:  1997-02       Impact factor: 3.517

Review 4.  Optimal management of gout in older patients.

Authors:  E B Gonzalez; S B Miller; C A Agudelo
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

5.  Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis.

Authors:  L B Siegel; J A Alloway; D J Nashel
Journal:  J Rheumatol       Date:  1994-07       Impact factor: 4.666

6.  Allopurinol in renal failure and the tumour lysis syndrome.

Authors:  H A Simmonds; J S Cameron; G S Morris; P M Davies
Journal:  Clin Chim Acta       Date:  1986-10-31       Impact factor: 3.786

7.  Gout in the elderly, a separate entity?

Authors:  E J ter Borg; J J Rasker
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

8.  A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis.

Authors:  M B Ferraz; B O'Brien
Journal:  J Rheumatol       Date:  1995-05       Impact factor: 4.666

Review 9.  Risks and benefits of drugs used in the management and prevention of gout.

Authors:  P G Conaghan; R O Day
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

10.  Gouty arthritis in nodal osteoarthritis.

Authors:  A G Fam; J Stein; J Rubenstein
Journal:  J Rheumatol       Date:  1996-04       Impact factor: 4.666

View more
  13 in total

1.  An elderly woman with a warm, painful finger.

Authors:  J M Geiderman
Journal:  West J Med       Date:  2000-01

2.  Gout. Easy to misdiagnose.

Authors:  R D Sturrock
Journal:  BMJ       Date:  2000-01-15

Review 3.  Identification of crystals in synovial fluids and joint tissues.

Authors:  A K Rosenthal; N Mandel
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.592

Review 4.  Recent advances in the epidemiology of gout.

Authors:  Kenneth G Saag; Ted R Mikuls
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

5.  Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.

Authors:  K Turnheim; P Krivanek; R Oberbauer
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 6.  Pathophysiology, clinical presentation and treatment of gout.

Authors:  Gim Gee Teng; Raj Nair; Kenneth G Saag
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Calcium oxalate stone and gout.

Authors:  Y M Fazil Marickar
Journal:  Urol Res       Date:  2009-09-25

Review 8.  Management of hyperuricemia in gout: focus on febuxostat.

Authors:  Mattheus K Reinders; Tim L Th A Jansen
Journal:  Clin Interv Aging       Date:  2010-02-02       Impact factor: 4.458

Review 9.  Systemic corticosteroids for acute gout.

Authors:  H J E M Janssens; P L B J Lucassen; F A Van de Laar; M Janssen; E H Van de Lisdonk
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

10.  Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury.

Authors:  Tamami Tanaka; Kent Doi; Rui Maeda-Mamiya; Kousuke Negishi; Didier Portilla; Takeshi Sugaya; Toshiro Fujita; Eisei Noiri
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.